Phase 1B Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

Authors

Kevin Judy, MD, MBA, Thomas Jefferson UniversityFollow

Document Type

Presentation

Presentation Date

11-11-2022

Comments

Presentation: 46:22

Abstract

Microglia and macrophages are the most abundant noncancerous cells in GBM constituting up to 40% of total tumor composition.

• Microglia can acquire an M1 phenotype characterized to release proinflammatory cytokines/mediators such as: IL-1B, IL-6, TNF-A, CCL2, reactive oxygen species (ROS), nitric oxide (NO).
• Microglia can also express an M2 phenotype associates with the ability to produce anti-inflammatory and immune suppressive factors such as: ARG-1, YM-1, CP36 and to upregulate cell surface markers CD163, CD204, CD206 and anti-inflammatory cytokines such as IL10.

Recommended Citation

Judy, MD, MBA, Kevin, "Phase 1B Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma" (2022). Department of Neurosurgery Presentations and Grand Rounds. Presentation 11.
https://jdc.jefferson.edu/neurosurgerygr/11

Language

English